Dhanapalaratnam Roshan, Issar Tushar, Poynten Ann M, Milner Kerry-Lee, Kwai Natalie C G, Krishnan Arun V
School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Department of Neurology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
J Neurophysiol. 2025 Jan 1;133(1):14-21. doi: 10.1152/jn.00228.2024. Epub 2024 Nov 25.
Diabetic peripheral neuropathy (DPN) affects approximately half of the 500 million people with type 2 diabetes worldwide. Previous studies have suggested that glucagon-like peptide-1 (GLP-1) receptors in the peripheral nervous system may be a suitable target for DPN treatment. Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes. Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy. These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken. Clinical neuropathy scores improved at 3 mo following commencement of GLP-1 (baseline TNS 3.7 ± 4.5, posttreatment TNS 2.3 ± 3.4, = 0.005). Nerve conduction studies demonstrated an improvement in sural amplitude at 3 mo (baseline 11.9 ± 8.5 μV, posttreatment 14.2 ± 9.2 μV; = 0.013). Axonal excitability studies revealed changes consistent with improvements in Na/K-ATPase pump function and Na permeability, and this was supported by mathematical modeling. GLP-1RA therapy improves clinical and neurophysiological outcomes in DPN. Treatment with GLP-1RA may reverse axonal dysfunction by improving Na/K-ATPase pump function. Diabetic peripheral neuropathy is known to be relentlessly progressive and irreversible. Prospective studies in 24 participants with diabetic peripheral neuropathy (DPN) treated with glucagon-like peptide-1 receptor agonists (GLP-1RA) demonstrated improvements in clinical neuropathy scores, nerve conduction studies, and axonal excitability recordings. Analysis of axonal excitability recordings revealed the mechanism for GLP-1RA improvement in DPN were changed consistent with improvements in Na/K-ATPase pump function, and this was supported by mathematical modeling.
全球约5亿2型糖尿病患者中,约有一半受到糖尿病周围神经病变(DPN)的影响。先前的研究表明,外周神经系统中的胰高血糖素样肽-1(GLP-1)受体可能是DPN治疗的合适靶点。作为2型糖尿病标准临床护理的一部分,14名连续招募的参与者在被处方司美格鲁肽或度拉糖肽后入组。参与者在基线时以及GLP-1受体激动剂(GLP-1RA)治疗开始后的3个月接受了临床评估、神经传导研究和轴突兴奋性评估。这些数据与10名先前接受艾塞那肽治疗的参与者的数据相结合,并对兴奋性数据进行了数学建模。GLP-1治疗开始后3个月,临床神经病变评分有所改善(基线总神经病变评分3.7±4.5,治疗后总神经病变评分2.3±3.4,P=0.005)。神经传导研究表明,3个月时腓肠神经波幅有所改善(基线11.9±8.5μV,治疗后14.2±9.2μV;P=0.013)。轴突兴奋性研究显示出与钠钾ATP酶泵功能和钠通透性改善一致的变化,数学建模也支持了这一点。GLP-1RA治疗可改善DPN的临床和神经生理学结果。GLP-1RA治疗可能通过改善钠钾ATP酶泵功能来逆转轴突功能障碍。已知糖尿病周围神经病变是持续进展且不可逆的。对24名接受胰高血糖素样肽-1受体激动剂(GLP-1RA)治疗的糖尿病周围神经病变(DPN)患者进行的前瞻性研究表明,临床神经病变评分、神经传导研究和轴突兴奋性记录均有改善。对轴突兴奋性记录的分析显示,GLP-1RA改善DPN的机制与钠钾ATP酶泵功能的改善一致,数学建模也支持了这一点。